Table 7.
Drugs used for prevention and treatment of osteoporosis
| Medication | Postmenopausal osteoporosis | Glucocorticoid induced osteoporosis | In Men | ||
|---|---|---|---|---|---|
|
|
|
|
|||
| Prevention | Treatment | Prevention | Treatment | Treatment | |
| Estrogen | Multiple regimens | ||||
| Denosumab | 60 mg sc/6mo | ||||
| Raloxifene | 60mg po/d | 60 mg po/d | |||
| Ibandronate | 2.5 mg po/d | 2.5 mg po/d | |||
| 150 mg/mo | 150 mg po/mo | ||||
| 3 mg iv/3mo | |||||
| Alendronate 5–10–70 mg | 5 mg po/d | 10 mg po/d | 5 mg po/d | 10 mg po/d | |
| 35 mg po/wk | 70 mg po/wk | 10mg po/d | 70 mg po/wk | ||
| 70mg po+VD | |||||
| Risedronate 5–35–75 mg | 5 mg po/d | 5 mg po/d | 5 mg po/d | 5 mg po/d | 35 mg po/wk |
| 35 mg po/wk | 150 mg po/mo | ||||
| 150 mg/po/mo | |||||
| Stronsium Ranelate 2gr po, eff | 2 gr/d | 2 gr/d | 2 gr/d | ||
| Zoledronic acid | 5mg iv/2 yr | 5 mg iv/yr | 5 mg iv/yr | 5 mg iv/yr | 5 mg iv/yr |
| Teriparatid | 20 ug sc/d | 20 ug sc/yr | 20 ug sc/d | ||
iv:intravenous; po: oral; sc: subcutaneous; eff: effervescent yr: year; wk: week; mo: month; d: day